<DOC>
	<DOCNO>NCT01584908</DOCNO>
	<brief_summary>Influenza important public health problem . Organ transplant patient particularly susceptible severe disease . Also , shed high quantity virus long duration , lead great contagious potential , thereby potentially serve node spread community . Therefore , improved strategy prevent influenza population important public health concern . Standard vaccination poorly immunogenic post-transplant new vaccine strategy need . Adjuvanted vaccine contain molecule create strong local inflammatory response attract immune cell site injection , increase immunogenicity vaccine antigen . Recently seasonal influenza vaccine contain adjuvant become available Canada limit information transplant patient . This randomized trial design assess immunogenicity adjuvanted vaccination strategy compare standard vaccine seasonal influenza cohort adult organ transplant recipient .</brief_summary>
	<brief_title>Adjuvanted Influenza Vaccine Evaluation Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Adult kidney transplant recipient Greater 3 month posttransplant Has already receive influenza vaccination 20122013 season Egg allergy Previous lifethreatening reaction influenza vaccine ( i.e . Guillain Barre Syndrome ) Ongoing therapy rejection Febrile illness past two week Unable provide inform consent Unable comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>kidney transplant recipient</keyword>
</DOC>